Review of direct-acting antiviral agents for the treatment of chronic hepatitis C

Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C

(2013) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

(2013) J. Guedj et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections

(2011) Graham R. Foster et al.   GASTROENTEROLOGY

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

(2011) Jean-Michel Pawlotsky   HEPATOLOGY

Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir

(2011) Simone Susser et al.   JOURNAL OF CLINICAL VIROLOGY

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

(2011) S. Zeuzem et al.   JOURNAL OF HEPATOLOGY

66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R

(2011) M.S. Sulkowski et al.   JOURNAL OF HEPATOLOGY

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION

(2011) M.S. Sulkowski et al.   JOURNAL OF HEPATOLOGY

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

(2011) A. Lok et al.   JOURNAL OF HEPATOLOGY

Hepatitis C virus resistance to protease inhibitors

(2011) Philippe Halfon et al.   JOURNAL OF HEPATOLOGY

Cyclophilin A Interacts with Domain II of Hepatitis C Virus NS5A and Stimulates RNA Binding in an Isomerase-Dependent Manner

(2011) T. L. Foster et al.   JOURNAL OF VIROLOGY

Future treatment of patients with HCV cirrhosis

(2011) Marc Bourlière et al.   LIVER INTERNATIONAL

Treatment of acute HCV infection

(2011) Jason Grebely et al.   Nature Reviews Gastroenterology & Hepatology

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induced-Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target

(2010) Maxwell D. Cummings et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

(2010) O. Lenz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs

(2010) Jun Su et al.   HEPATOLOGY

Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral Target

(2010) Kevin D. Raney et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

2007 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAIVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS

(2010) D. Larrey et al.   JOURNAL OF HEPATOLOGY

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

(2010) J.M. Vierling et al.   JOURNAL OF HEPATOLOGY

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

(2010) Edward J Gane et al.   LANCET

Review: New direct-acting antivirals in the development for hepatitis C virus infection

(2010) Paul J. Pockros   Therapeutic Advances in Gastroenterology

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

(2009) Raf Crabbé et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

The global burden of hepatitis C

(2009) Daniel Lavanchy   LIVER INTERNATIONAL

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY

Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein

(2008) Timothy L. Tellinghuisen et al.   PLoS Pathogens